Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Asta Theodorsdottir, Syddansk Universitet
  • ,
  • Birgit Debrabant, Syddansk Universitet
  • ,
  • Melinda Magyari, Københavns Universitet
  • ,
  • Matthias Kant, Hospital of Southern Jutland
  • ,
  • Peter V. Rasmussen
  • Carl Fredrik Malmberg, Syddansk Universitet
  • ,
  • Iver A. Norberg, Syddansk Universitet
  • ,
  • Victoria Hansen, Aalborg Universitet
  • ,
  • Danny Bech, Aarhus Universitet
  • ,
  • Mathias F. Schmidt, Københavns Universitet
  • ,
  • Karen Schreiber, Københavns Universitet
  • ,
  • Jette L. Frederiksen, Københavns Universitet
  • ,
  • Finn Sellebjerg, Københavns Universitet
  • ,
  • Zsolt Illes, Syddansk Universitet

Objective: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark. Methods: Data were retrieved from The Danish Multiple Sclerosis Registry between 2009 and 2019. Demographic and disease-specific patient parameters related to treatment history, efficacy, and safety outcomes were assessed at baseline and during follow-up visits. Results: A total of 209 patients (78% female) started treatment with alemtuzumab during the study period with 3.1 ± 1.4 years follow-up. After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab (p < 0.001). The annual number of relapses was reduced by 69% in year 4 compared with the year prior alemtuzumab. More active disease before alemtuzumab increased the annual hazard rate for relapse (HR: 2.88, p < 0.001). The Expanded Disability Status Scale (EDSS) score remained stable or improved in 81% of patients after 2 years. The need for an additional treatment course was associated with higher number of relapses in the year before alemtuzumab (odds ratio (OR) = 1.95, p = 0.001). Conclusion: In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed.

OriginalsprogEngelsk
TidsskriftMultiple Sclerosis Journal
Vol/bind27
Nummer14
Sider (fra-til)2254-2266
Antal sider13
ISSN1352-4585
DOI
StatusUdgivet - dec. 2021

Se relationer på Aarhus Universitet Citationsformater

ID: 226835982